228 related articles for article (PubMed ID: 18328956)
21. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
[TBL] [Abstract][Full Text] [Related]
22. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.
Nascimento E; Fernandes DF; Vieira EP; Campos-Neto A; Ashman JA; Alves FP; Coler RN; Bogatzki LY; Kahn SJ; Beckmann AM; Pine SO; Cowgill KD; Reed SG; Piazza FM
Vaccine; 2010 Sep; 28(40):6581-7. PubMed ID: 20688040
[TBL] [Abstract][Full Text] [Related]
23. Papular dermatitis due to Leishmania infantum infection in seventeen dogs: diagnostic features, extent of the infection and treatment outcome.
Lombardo G; Pennisi MG; Lupo T; Chicharro C; Solano-Gallego L
Parasit Vectors; 2014 Mar; 7():120. PubMed ID: 24661822
[TBL] [Abstract][Full Text] [Related]
24. Changes in the concentration of anti-Leishmania antibodies in saliva of dogs with clinical leishmaniosis after short-term treatment.
Cantos-Barreda A; Escribano D; Cerón JJ; Tecles F; Bernal LJ; Martínez-Subiela S
Vet Parasitol; 2018 Apr; 254():135-141. PubMed ID: 29656998
[TBL] [Abstract][Full Text] [Related]
25. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment.
Gradoni L; Maroli M; Gramiccia M; Mancianti F
Med Vet Entomol; 1987 Oct; 1(4):339-42. PubMed ID: 2979550
[TBL] [Abstract][Full Text] [Related]
26. Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates.
Grimaldi G; Teva A; Dos-Santos CB; Santos FN; Pinto ID; Fux B; Leite GR; Falqueto A
PLoS One; 2017; 12(9):e0185438. PubMed ID: 28953944
[TBL] [Abstract][Full Text] [Related]
27. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
[TBL] [Abstract][Full Text] [Related]
28. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
[TBL] [Abstract][Full Text] [Related]
29. Studies on canine leishmaniasis control. 2. Effectiveness of control measures against canine leishmaniasis in the Isle of Elba, Italy.
Gradoni L; Gramiccia M; Mancianti F; Pieri S
Trans R Soc Trop Med Hyg; 1988; 82(4):568-71. PubMed ID: 3256109
[TBL] [Abstract][Full Text] [Related]
30. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
[TBL] [Abstract][Full Text] [Related]
31. Immunoprophylactic Potential of a New Recombinant
Pessoa-E-Silva R; Trajano-Silva LAM; Vaitkevicius-Antão V; Dos Santos WJT; Magalhães FB; Moura DMN; Nakasone EKN; de Lorena VMB; de Paiva-Cavalcanti M
Front Immunol; 2020; 11():605044. PubMed ID: 33488607
[TBL] [Abstract][Full Text] [Related]
32. First report of the use of meglumine antimoniate for treatment of canine leishmaniasis in a pregnant dog.
Spada E; Proverbio D; Groppetti D; Perego R; Grieco V; Ferro E
J Am Anim Hosp Assoc; 2011; 47(1):67-71. PubMed ID: 21164165
[TBL] [Abstract][Full Text] [Related]
33. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
Pourabbas B; Ghadimi Moghadam A; Pouladfar G; Rezaee Z; Alborzi A
Am J Trop Med Hyg; 2013 May; 88(5):868-71. PubMed ID: 23400573
[TBL] [Abstract][Full Text] [Related]
34. Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil.
Regina-Silva S; Feres AM; França-Silva JC; Dias ES; Michalsky ÉM; de Andrade HM; Coelho EA; Ribeiro GM; Fernandes AP; Machado-Coelho GL
Vaccine; 2016 Apr; 34(19):2233-9. PubMed ID: 26997002
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
[TBL] [Abstract][Full Text] [Related]
37. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
[TBL] [Abstract][Full Text] [Related]
38. Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate.
Ikeda-Garcia FA; Lopes RS; Marques FJ; de Lima VM; Morinishi CK; Bonello FL; Zanette MF; Perri SH; Feitosa MM
Vet Parasitol; 2007 Feb; 143(3-4):254-9. PubMed ID: 16996214
[TBL] [Abstract][Full Text] [Related]
39. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
[TBL] [Abstract][Full Text] [Related]
40. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis.
Fernandes CB; Junior JT; de Jesus C; Souza BM; Larangeira DF; Fraga DB; Tavares Veras PS; Barrouin-Melo SM
Vaccine; 2014 Mar; 32(11):1287-95. PubMed ID: 24406392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
